Jasper Ridge Partners’s Esperion Therapeutics ESPR Stock Holding History

Jasper Ridge Partners’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,773	Closed	-$207K	–	145
2021 Q2	$207K	Hold	9,773	–	–	0.01%	128
2021 Q1	$274K	Hold	9,773	–	–	0.01%	108
2020 Q4	$254K	Hold	9,773	–	–	0.01%	105
2020 Q3	$363K	Hold	9,773	–	–	0.02%	101
2020 Q2	$501K	Hold	9,773	–	–	0.03%	83
2020 Q1	$308K	Hold	9,773	–	–	0.02%	84
2019 Q4	$583K	Hold	9,773	–	–	0.04%	74
2019 Q3	$358K	Hold	9,773	–	–	0.02%	75
2019 Q2	$455K	Hold	9,773	–	–	0.02%	71
2019 Q1	$392K	Hold	9,773	–	–	0.02%	69
2018 Q4	$450K	Hold	9,773	–	–	0.03%	54
2018 Q3	$434K	Hold	9,773	–	–	0.02%	59
2018 Q2	$383K	Hold	9,773	–	–	0.03%	57
2018 Q1	$707K	Hold	9,773	–	–	0.04%	44
2017 Q4	$643K	Buy	+9,773	New	+$526K	0.04%	43

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jasper Ridge Partners's ESPR Position: Q3 2021 in Review

Jasper Ridge Partners sold out of Esperion Therapeutics (ESPR) in Q3 2021, closing a stake of 9,773 shares — an estimated $207K sold.

Jasper Ridge Partners first reported a position in ESPR in Q4 2017 and held it in 15 quarters. The position peaked at $707K in Q1 2018. 139 funds tracked by Wall St. Rank hold ESPR as of Q3 2021.

Jasper Ridge Partners reported no remaining Esperion Therapeutics position as of Q3 2021 after selling out during the quarter.
Jasper Ridge Partners sold 9,773 Esperion Therapeutics shares in Q3 2021, an estimated $207K.
Jasper Ridge Partners first reported a position in Esperion Therapeutics in Q4 2017 and held it in 15 quarters.
Jasper Ridge Partners's Esperion Therapeutics position peaked at $707K in Q1 2018.
139 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2021.

Based on Jasper Ridge Partners's 13F filing for Q3 2021, filed 12 Nov 2021.